Molecular interactions in imatinib–DPPC liposomes.

Béni, Szabolcs and Budai, Marianna and Noszál, Béla and Gróf, Pál (2006) Molecular interactions in imatinib–DPPC liposomes. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 27. pp. 205-211. ISSN 0928-0987

Text 1234173.pdf Restricted to Repository staff only Download (291kB) | Request a copy

Abstract

Imatinib (Gleevec®) is a novel chemotherapeutic agent against Bcr-Abl protein tyrozine kinase, playing a crucial role in the therapy of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Our study aimed at designing a liposomal imatinib formulation and investigating molecular interactions between lipid and imatinib, within the liposomal membrane. Multilamellar (MLV) and small unilamellar (SUV) vesicles were prepared from alfa-l-dipalmitoyl-phosphatidylcholine (DPPC). The effect of imatinib on the DPPC membrane was studied by electron paramagnetic resonance (EPR) spectroscopy and differential scanning calorimetry (DSC), at pH 5.2 and 9.0, where imatinib is in monocationic and neutral form, respectively. Our results indicate that imatinib interacts mainly with the DPPC head groups, leading to a slight increase in the mobility of the polar headgroups in case of MLVs. Contrary to that, imatinib causes a significant decrease in the fluidity of SUVs, which can be the result of a pH-dependent fusion/fission effect. The size distribution and morphology of liposomeswere checked by dynamic light scattering and freeze-fracture electron microscopy. Our results direct attention to investigate the interactions of imatinib with artificial/biological membranes.

Actions (login required)

Edit Item